May 17, 2019   SOURCE: PR NewsWire

Orexo's Closest Upcoming Presentations at Conferences

UPPSALA, Sweden, May 17, 2019 /PRNewswire/ -- Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting at the following events taking place in May and June.

                                                                        Date & local time                                Presentor

                            Event              City




     Nordic Biotech &
      Pharma 2019                 
     Copenhagen      May 29, 3.45 pm                                CEO, Nikolaj Sørensen


     Aktiespararnas
      Smabolagsdag                                                                                 CEO, Nikolaj Sørensen

                                  
     Stockholm       June 3, 2.00 pm


                                                                                                   CEO, Nikolaj Sørensen

     Handelsbanken Mid and
      Small Cap Seminar           
     Stockholm       June 4, 12.50 pm



                                                                                           President of Orexo US Inc.,
                                                                                           Robert A. DeLuca and
     Jefferies 2019 Global
      Healthcare Conference       
     New York        June 4, 11.30[1] am                   CFO, Joseph DeFeo



                                                    June, 10, 4.10 pm

     Redeye Growth Day            
     Stockholm                                                      CEO, Nikolaj Sørensen

[1] timing of presentation to be confirmed, see www.orexo.com and calendar.

For further information, please contact:

Orexo AB (publ.)
Lena Wange, IR and Communications Manager
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid addiction and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

The information was submitted for publication at 3 pm CET on May 17, 2019

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-s-closest-upcoming-presentations-at-conferences,c2818249

The following files are available for download:


     
     https://mb.cision.com/Main/694/2818249/1047448.pdf Press release (PDF)

View original content:http://www.prnewswire.com/news-releases/orexos-closest-upcoming-presentations-at-conferences-300852412.html

SOURCE Orexo